長時間作用型ドラッグデリバリー技術およびサービス市場：世界および地域別分析（2023年～2033年）

2022年現在、世界の長時間作用型ドラッグデリバリー技術およびサービス市場は114億1,000万米ドルの規模を保持しています。

同市場は2023～2033年の予測期間中にCAGR 11.31%で成長し、2033年には368億2,000万米ドルに達すると予測されています。同市場の軌跡は、医薬品医療に変革的な影響を与えることを示唆しており、規制の複雑さに対処し、技術革新を取り入れることに長けた企業が大きな成功を収める態勢を整えています。

主要市場統計
予測期間	2023-2033
2023年の評価額	126億1,000万米ドル
2033年予測	368億2,000万米ドル
CAGR	11.31%

世界の長時間作用型ドラッグデリバリー技術およびサービス市場は成長段階にあります。需要と採用の大幅な増加を特徴とするこの段階は、長時間作用型ドラッグデリバリーソリューションの認知度と受容度の高まりを反映しています。慢性疾患の有病率の増加、技術の進歩、患者中心のアプローチへのシフトなどの主な促進要因が市場を前進させています。革新的な製剤とデリバリーシステムが支持を集め、製薬・技術部門間の投資を誘致し、協力関係を促進しています。規制の複雑さやコスト面などの課題は依然として存在するもの、全体的な軌道は市場のダイナミックな拡大を示唆しています。

特に新興地域や治療用途における市場拡大の機会は、成長段階の特徴をさらに際立たせています。業界が進化を続ける中、課題を効果的に克服し、チャンスを生かす企業は、長時間作用型ドラッグデリバリー技術およびサービス市場の成熟と持続可能性に貢献する好位置につけています。

長時間作用型ドラッグデリバリー技術およびサービスが業界に与える影響は大きく、製薬・ヘルスケア分野の様々な側面に影響を及ぼしています。重大な影響の一つは、患者の転帰とアドヒアランスに見られます。長時間作用型ドラッグデリバリーシステムの採用は、患者のアドヒアランスの向上に寄与します。なぜなら、これらの技術は投与回数が少なくて済むことが多く、投与漏れの可能性を減らし、全体的な治療効果を高めるからです。このような患者の転帰への好影響は、ヘルスケアの質を高めるだけでなく、未治療や最適でない治療に関連する医療費を削減する可能性もあります。

さらに、この市場は製薬業界における技術革新と協力の波にも拍車をかけています。各社は新しい製剤やデリバリー方法を生み出すための研究開発に投資しており、効率性と患者中心のソリューションを優先する競合情勢を醸成しています。製薬科学者、エンジニア、臨床医による学際的コラボレーションの出現は、従来のドラッグデリバリーメカニズムを超える最先端技術の開発を加速させています。

当レポートでは、世界の長時間作用型ドラッグデリバリー技術およびサービス市場について調査し、市場の概要とともに、技術別、剤形別、分子タイプ別、使用材料別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 範囲と定義

第2章 市場：業界の見通し

第3章 世界の長時間作用型ドラッグデリバリー技術およびサービス市場（技術別）、2022年～2033年

• 技術の概要
• 長時間作用型注射剤
• 長時間作用型ヒドロゲル
• 長時間作用型インプラント
• 長時間作用型マイクロニードル
• ナノクリスタルサスペンション

第4章 世界の長時間作用型ドラッグデリバリー技術およびサービス市場（剤形別）、2022年～2033年

• 剤形の概要
• 長時間作用型注射剤
• 長時間作用型植込型
• 局所/経皮
• 膣
• その他

第5章 世界の長時間作用型ドラッグデリバリー技術およびサービス市場（分子タイプ別）、2022年～2033年

• 分子タイプの概要
• 低分子
• 生物製剤
• その他の分子（ペプチド）

第6章 世界の長時間作用型ドラッグデリバリー技術およびサービス市場（使用材料別）、2022年～2033年

• 使用材料の概要
• ポリマーベース
• 非ポリマーベース

第7章 世界の長時間作用型ドラッグデリバリー市場（流通チャネル別）、2022年～2033年

• 流通チャネルの概要
• 病院と薬局
• 調査と学術
• その他

第8章 世界の長時間作用型ドラッグデリバリー技術およびサービス市場、地域別、2022年～2033年

• 地域別との概要
• 促進要因と抑制要因
• 北米
• 欧州
• アジア太平洋
• その他の地域

第9章 市場-競合ベンチマーキングと企業プロファイル

• 競合情勢
• Adare Pharma Solutions
• Alkermes
• AMW Gmb
• Camurus AB
• Corium, LLC.
• Creative Biolabs
• Delpor, Inc.
• Durect Corporation
• Hanmi Pharm Co Ltd.
• Heron Therapeutics, Inc.
• Integral BioSystems
• NANEXA AB

“Global Long-Acting Drug Delivery Technologies and Services Market Expected to Reach $36.82 Billion by 2033.”

Market Overview

As of 2022, the global long-acting drug delivery technologies and services market held a value of $11.41 billion. The market is expected to grow at a CAGR of 11.31% during the forecast period 2023-2033 and attain a value of $36.82 billion by 2033. The market's trajectory suggests a transformative impact on pharmaceutical care, with companies adept at addressing regulatory complexities and embracing technological innovations poised for significant success.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$12.61 Billion
2033 Forecast	$36.82 Billion
CAGR	11.31%

Market Lifecycle Stage

The global long-acting drug delivery technologies and services market is in a growing phase. Characterized by a significant increase in demand and adoption, this stage reflects the rising recognition and acceptance of long-acting drug delivery solutions. Key drivers, including the growing prevalence of chronic diseases, technological advancements, and a shift toward patient-centric approaches, are propelling the market forward. Innovative formulations and delivery systems are gaining traction, attracting investments and fostering collaborations across pharmaceutical and technology sectors. While challenges such as regulatory complexities and cost considerations persist, the overall trajectory suggests a dynamic and expanding market.

Opportunities for market expansion, particularly in emerging regions and therapeutic applications, further underscore the growth stage characteristics. As the industry continues to evolve, companies that effectively navigate challenges and capitalize on opportunities are well-positioned to contribute to the maturity and sustainability of the long-acting drug delivery technologies and services market.

Industry Impact

The industry impact of long-acting drug delivery technologies and services is profound, influencing various facets of the pharmaceutical and healthcare sectors. One significant effect is observed in patient outcomes and adherence. The adoption of long-acting drug delivery systems contributes to improved patient adherence, as these technologies often require less frequent dosing, reducing the likelihood of missed doses and enhancing overall treatment efficacy. This positive impact on patient outcomes not only enhances the quality of healthcare but also potentially reduces healthcare costs associated with untreated or sub-optimally treated conditions.

Furthermore, the market has spurred a wave of innovation and collaboration within the pharmaceutical industry. Companies are investing in research and development to create novel drug formulations and delivery methods, fostering a competitive landscape that prioritizes efficiency and patient-centric solutions. The emergence of interdisciplinary collaborations between pharmaceutical scientists, engineers, and clinicians is accelerating the development of cutting-edge technologies that go beyond traditional drug delivery mechanisms.

Market Segmentation:

Segmentation 1: by Technique

• Long-Acting Injectables
• Long-Acting Hydrogels
• Long-Acting Implants
• Long-Acting Microneedles
• Nanocrystal Suspensions

Long-Acting Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Technique)

The long-acting injectables segment dominated the global long-acting drug delivery technologies and services market (by technique) in FY2022. The increasing preference for injectable formulations stems from their ability to provide sustained drug release over an extended period, offering advantages such as reduced dosing frequency and enhanced patient compliance. This dominance is particularly evident in therapeutic areas where a consistent and prolonged therapeutic effect is crucial, such as chronic diseases and certain mental health conditions.

Segmentation 2: by Dosage Form

• Injectables
• Implantable
• Topical/Transdermal
• Vaginal
• Other Dosage Forms

Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Dosage Form)

The injectables segment dominated the global long-acting drug delivery technologies and services market (by dosage forms) in FY2022. Injectables are characterized by sustained and controlled drug release through injection, are gaining prominence across various therapeutic areas, thereby reshaping the landscape of long-acting drug delivery solutions.

Segmentation 3: by Type of Molecule Delivered

• Small Molecules
• Biologics
• Other Molecules

Small Molecules to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Type of Molecule Delivered)

The global long-acting drug delivery technologies and services market (by type of molecule delivered) was dominated by the small molecules segment in FY2022. Small molecules, characterized by their molecular size and structure, are poised to take center stage in this market, driven by their versatility, widespread therapeutic applications, and advancements in drug formulation technologies.

Segmentation 4: by Material Used

• Polymer Based
• Non-Polymer Based

Polymer Based to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Material Used)

The global long-acting drug delivery technologies and services market (by material used) was dominated by the polymer based segment in FY2022. This trend reflects a strategic shift toward the utilization of polymers for the development of long-acting drug delivery systems, driven by their versatility, biocompatibility, and ability to modulate drug release profiles effectively.

Segmentation 5: by End User

• Biopharmaceutical and Life science Companies
• Research and Academics

Biopharmaceutical and Life science Companies to Continue its Dominance in the Global Long-Acting Drug Delivery Technologies and Services Market (by End User)

The Biopharmaceutical and Life science Companies segment accounted for the largest share of the global long-acting drug delivery technologies and services market (by End User) in FY2022. Biopharmaceutical and life science companies are poised to sustain their dominant role in the global long-acting drug delivery technologies and services market as primary end users. This enduring dominance can be attributed to several key factors that highlight the pivotal role these companies play in driving innovation, research, and development within the pharmaceutical industry.

Segmentation 6: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

China dominated the Asia-Pacific market in 2022 with a share of 36.40%. Moreover, Asia-Pacific is expected to register the highest CAGR of 12.70% during the forecast period 2023-2033. The long-acting drug delivery technologies and services market in the Asia-Pacific (APAC) region is witnessing significant growth, marked by increasing demand, technological advancements, and a shifting healthcare landscape. This growth reflects a convergence of factors contributing to the adoption and expansion of long-acting drug delivery solutions across diverse therapeutic areas.

Recent Developments in the Global Long-Acting Drug Delivery Technologies and Services Market

• In August 2023, AMW GmbH opened new European and international markets with its goserelin implant's first Notified Body Opinion (NBO) report.

• In November, AMW GmbH and AdhexPharma announced a strategic partnership for transdermal delivery systems.

• In February 2023, Innocore Pharmaceuticals, a Dutch pharmaceutical company specializing in the development of polymer-based long-acting injectables, secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch for effective and simplified vaccine administration.

• In March 2023, DelSiTech was granted to develop controlled and sustained-release injectables for the prophylactic HIV vaccine.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

Growing adoption of sustained release drugs and technologies: The increasing adoption of sustained release drugs and related technologies is a key driver for the growth of the long-acting drug delivery technologies and services market. This trend reflects a shift toward developing pharmaceutical products that offer prolonged therapeutic effects, reducing the frequency of drug administration and improving patient compliance.

Market Restraints:

Limitations of long-acting drug delivery technologies: The global long-acting drug delivery technologies and services market faces hindrances due to several limitations associated with these technologies. These challenges impact the widespread adoption and growth of the market. Some key limitations include the potential for a delayed onset of action, restricting their use in situations requiring rapid therapeutic effects.

Market Opportunities:

Introduction of biologics and biosimilars compatibility in technologies: The further evolution of the development of biologics and biosimilars compatible long-acting drug delivery technologies acts as an opportunity for the market. These technologies are expected to open the potential of treating different therapeutic areas that are biologic and biosimilar dependent via long-acting drug delivery systems.

How can this report add value to an organization?

Workflow/Innovation Strategy: The long-acting drug delivery technologies and services market (by technique) has been segmented into detailed segments of techniques, including different types of techniques such as long-acting injectables, long-acting hydrogels, long-acting implants, long-acting microneedles, and nanocrystal suspensions. Moreover, the study provides the reader with a detailed understanding of the different types of molecules delivered and the material used.

Growth/Marketing Strategy: The long-acting drug delivery technologies and services market encompasses a range of products and services designed to extend the duration of drug action. These technologies aim to improve patient compliance, reduce the frequency of drug administration, and enhance the overall efficacy of therapeutic interventions. This market includes various drug delivery systems and services that provide sustained release, controlled release, or targeted drug delivery over an extended period.

Competitive Strategy: Key players in the global long-acting drug delivery technologies and services market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global long-acting drug delivery technologies and services market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
• The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2023 to 2033.
• The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of offerings to the long-acting drug delivery technologies and services market have been considered and profiled in the report.
• In the study, the primary respondent's verification has been considered to finalize the estimated market for the long-acting drug delivery technologies and services market.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), and World Health Organization (WHO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The long-acting drug delivery technologies and services competition seeks to catalyze innovation in the field of pharmaceuticals by encouraging the development of novel, efficient, and patient-friendly drug delivery systems. This competition aims to address the challenges associated with traditional drug administration methods, such as frequent dosing and patient adherence, by promoting the exploration and implementation of long-acting drug delivery technologies.

The global market for long-acting drug delivery technologies and services is experiencing substantial growth, driven by the escalating prevalence of chronic diseases and technological advancements in drug formulation and delivery systems. With a focus on patient-centric solutions and personalized medicine, these technologies offer a more convenient and efficient means of drug administration, improving patient adherence and treatment outcomes.

Some of the prominent companies in this market are:

Companies that are not a part of the aforementioned pool have been well-represented across different sections of the report (wherever applicable).

Table of Contents

1. Scope and Definition

• 1.1. Market Definition
• 1.2. Key Questions Answered in the Report
• 1.3. Analyst and Forecast Note

2. Markets: Industry Outlook

• 2.1. Current and Future State of Long-Acting Drug Delivery Technologies and Services in Industries
• 2.2. Key Benefits of Long-Acting Drug Delivery
• 2.3. Market Footprint and Growth Potential, $Million, 2022-2033
• 2.4. Market Dynamics Overview
• 2.5. Market Drivers
• 2.6. Market Restraints
• 2.7. Market Opportunities

3. Global Long-Acting Drug Delivery Technologies and Services Market (by Technique), 2022-2033

• 3.1. Technique Summary
• 3.2. Long-Acting Injectables
• 3.3. Long-Acting Hydrogels
• 3.4. Long-Acting Implants
• 3.5. Long-Acting Microneedles
• 3.6. Nanocrystal Suspensions

4. Global Long-Acting Drug Delivery Technologies and Services Market (by Dosage Forms), 2022-2033

• 4.1. Dosage Forms Summary
• 4.2. Long-acting Injectables
• 4.3. Long-acting Implantable
• 4.4. Topical / Transdermal
• 4.5. Vaginal
• 4.6. Other Dosage Forms

5. Global Long-Acting Drug Delivery Technologies and Services Market (by Type of Molecule Delivered), 2022-2033

• 5.1. Type of Molecule Delivered Summary
• 5.2. Small Molecules
• 5.3. Biologics
• 5.4. Other Molecules (Peptides)

6. Global Long-Acting Drug Delivery Technologies and Services Market (by Material Used), 2022-2033

• 6.1. Material-Used Summary
• 6.2. Polymer based
• 6.3. Non-polymer based

7. Global Long-Acting Drug Delivery Market (by Distribution Channels), 2022-2033

• 7.1. Distribution Channels Summary
• 7.2. Hospitals and Retail Pharmacies
• 7.3. Research and Academics
• 7.4. Others

8. Global Long-Acting Drug Delivery Technologies and Services Market, by Region, 2022-2033

• 8.1. Regional Summary
• 8.2. Drivers and Restraints
• 8.3. North America
  • 8.3.1. U.S.
  • 8.3.2. Canada
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. U.K.
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Rest-of-Europe
• 8.5. Asia Pacific
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. South Korea
  • 8.5.5. Australia
  • 8.5.6. Rest-of-Asia-Pacific
• 8.6. Rest-of-the-World

9. Markets - Competitive Benchmarking & Company Profiles

• 9.1. Competitive Landscape
• 9.2. Adare Pharma Solutions
• 9.3. Alkermes
• 9.4. AMW Gmb
• 9.5. Camurus AB
• 9.6. Corium, LLC.
• 9.7. Creative Biolabs
• 9.8. Delpor, Inc.
• 9.9. Durect Corporation
• 9.10. Hanmi Pharm Co Ltd.
• 9.11. Heron Therapeutics, Inc.
• 9.12. Integral BioSystems
• 9.13. NANEXA AB